These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
363 related articles for article (PubMed ID: 25605354)
1. Impact of the combination of daptomycin and trimethoprim-sulfamethoxazole on clinical outcomes in methicillin-resistant Staphylococcus aureus infections. Claeys KC; Smith JR; Casapao AM; Mynatt RP; Avery L; Shroff A; Yamamura D; Davis SL; Rybak MJ Antimicrob Agents Chemother; 2015 Apr; 59(4):1969-76. PubMed ID: 25605354 [TBL] [Abstract][Full Text] [Related]
2. Treatment of methicillin-resistant Staphylococcus aureus infections with a minimal inhibitory concentration of 2 μg/mL to vancomycin: old (trimethoprim/sulfamethoxazole) versus new (daptomycin or linezolid) agents. Campbell ML; Marchaim D; Pogue JM; Sunkara B; Bheemreddy S; Bathina P; Pulluru H; Chugh N; Wilson MN; Moshos J; Ku K; Hayakawa K; Martin ET; Lephart PR; Rybak MJ; Kaye KS Ann Pharmacother; 2012 Dec; 46(12):1587-97. PubMed ID: 23212935 [TBL] [Abstract][Full Text] [Related]
3. High dose of trimethoprim-sulfamethoxazole and daptomycin as a therapeutic option for MRSA endocarditis with large vegetation complicated by embolic stroke: a case report and literature review. Di Carlo P; D'Alessandro N; Guadagnino G; Bonura C; Mammina C; Lunetta M; Novo S; Giarratano A Infez Med; 2013 Mar; 21(1):45-9. PubMed ID: 23524901 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of the novel combination of high-dose daptomycin plus trimethoprim-sulfamethoxazole against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus using an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations. Steed ME; Werth BJ; Ireland CE; Rybak MJ Antimicrob Agents Chemother; 2012 Nov; 56(11):5709-14. PubMed ID: 22908167 [TBL] [Abstract][Full Text] [Related]
5. Daptomycin-nonsusceptible vancomycin-intermediate staphylococcus aureus vertebral osteomyelitis cases complicated by bacteremia treated with high-dose daptomycin and trimethoprim-sulfamethoxazole. Avery LM; Steed ME; Woodruff AE; Hasan M; Rybak MJ Antimicrob Agents Chemother; 2012 Nov; 56(11):5990-3. PubMed ID: 22869580 [TBL] [Abstract][Full Text] [Related]
6. Daptomycin therapy failure in an adolescent with methicillin-resistant Staphylococcus aureus bacteremia. Jacobson LM; Milstone AM; Zenilman J; Carroll KC; Arav-Boger R Pediatr Infect Dis J; 2009 May; 28(5):445-7. PubMed ID: 19295462 [TBL] [Abstract][Full Text] [Related]
7. Successful treatment of daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus bacteremia with the addition of rifampin to daptomycin. Ahmad NM; Rojtman AD Ann Pharmacother; 2010 May; 44(5):918-21. PubMed ID: 20354160 [TBL] [Abstract][Full Text] [Related]
8. Vancomycin plus ceftaroline shows potent in vitro synergy and was successfully utilized to clear persistent daptomycin-non-susceptible MRSA bacteraemia. Barber KE; Rybak MJ; Sakoulas G J Antimicrob Chemother; 2015 Jan; 70(1):311-3. PubMed ID: 25125677 [No Abstract] [Full Text] [Related]
9. Combination ceftaroline and daptomycin salvage therapy for complicated methicillin-resistant Staphylococcus aureus bacteraemia compared with standard of care. Johnson TM; Molina KC; Miller MA; Kiser TH; Huang M; Mueller SW Int J Antimicrob Agents; 2021 Apr; 57(4):106310. PubMed ID: 33609718 [TBL] [Abstract][Full Text] [Related]
10. Novel daptomycin combinations against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetations. Steed ME; Vidaillac C; Rybak MJ Antimicrob Agents Chemother; 2010 Dec; 54(12):5187-92. PubMed ID: 20921318 [TBL] [Abstract][Full Text] [Related]
11. A randomized phase 2B trial of vancomycin versus daptomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteremia due to isolates with high vancomycin minimum inhibitory concentrations - results of a prematurely terminated study. Kalimuddin S; Chan YFZ; Phillips R; Ong SP; Archuleta S; Lye DC; Tan TT; Low JGH Trials; 2018 Jun; 19(1):305. PubMed ID: 29859132 [TBL] [Abstract][Full Text] [Related]
12. Implementation of an antimicrobial stewardship pathway with daptomycin for optimal treatment of methicillin-resistant Staphylococcus aureus bacteremia. Kullar R; Davis SL; Kaye KS; Levine DP; Pogue JM; Rybak MJ Pharmacotherapy; 2013 Jan; 33(1):3-10. PubMed ID: 23307539 [TBL] [Abstract][Full Text] [Related]
13. Use of daptomycin to treat infections with methicillin-resistant Staphylococcus aureus isolates having vancomycin minimum inhibitory concentrations of 1.5 to 2 μg/mL. McDaneld PM; Spooner LM; Mohr JF; Belliveau PP Ann Pharmacother; 2013 Dec; 47(12):1654-65. PubMed ID: 24259618 [TBL] [Abstract][Full Text] [Related]
14. Daptomycin in combination with other antibiotics for the treatment of complicated methicillin-resistant Staphylococcus aureus bacteremia. Dhand A; Sakoulas G Clin Ther; 2014 Oct; 36(10):1303-16. PubMed ID: 25444563 [TBL] [Abstract][Full Text] [Related]
15. Community-phenotype-methicillin-resistant Staphylococcus aureus infections: a retrospective chart review of outcomes after treatment with daptomycin. Katz DE; Martone WJ Clin Ther; 2007 Nov; 29(11):2440-7. PubMed ID: 18158084 [TBL] [Abstract][Full Text] [Related]
16. Vancomycin or Daptomycin Plus a β-Lactam Versus Vancomycin or Daptomycin Alone for Methicillin-Resistant Yi YH; Wang JL; Yin WJ; Xu WH Microb Drug Resist; 2021 Aug; 27(8):1044-1056. PubMed ID: 33728980 [No Abstract] [Full Text] [Related]